{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "country": "United States",
      "city": "Horsham",
      "address_1": "425 Privet Rd",
      "reason_for_recall": "Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.",
      "address_2": "",
      "product_quantity": "1,249,700 tablets",
      "code_info": "lot #14071112AA; Exp. 03/14.   lot #14071112AB;  Exp. 03/14.   lot # 14071012BA;  Exp. 03/14.  lot #14071012BB;  Exp 03/14.",
      "center_classification_date": "20140204",
      "distribution_pattern": "Nationwide",
      "state": "PA",
      "product_description": "Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Republic By: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0554-89  (carton) and 00182-0554-00 (single blister).",
      "report_date": "20140212",
      "classification": "Class II",
      "openfda": {},
      "recalling_firm": "Teva Pharmaceuticals USA",
      "recall_number": "D-1074-2014",
      "initial_firm_notification": "Letter",
      "product_type": "Drugs",
      "event_id": "67141",
      "termination_date": "20141022",
      "more_code_info": "",
      "recall_initiation_date": "20131218",
      "postal_code": "19044-1220",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "status": "Terminated"
    }
  ]
}